We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

7 hedge funds and large institutions have $475K invested in Immix Biopharma in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $352K → $475K (+$123K)

0.61% less ownership

Funds ownership: 1.93% → 1.32% (-0.61%)

13% less funds holding

Funds holding: 8 → 7 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$143K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$99.4K
3
State Street
State Street
Massachusetts
+$75.3K
4
UBS Group
UBS Group
Switzerland
+$8.47K
5
Wells Fargo
Wells Fargo
California
+$86

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$151K
2
VF
Virtu Financial
New York
-$57K
3
Citadel Advisors
Citadel Advisors
Florida
-$52K
4
XT
XTX Topco
Cayman Islands
-$31K
5
BlackRock
BlackRock
New York
-$22K

IMMX Hedge Fund Activity: Q2 2022 in Review

7 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q2 2022, worth a combined $475K — up 35% from $352K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IMMX and 4 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $143K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $151K sold.

  • 7 institutional investors held Immix Biopharma (IMMX) as of Q2 2022, down from 8 in Q1 2022.
  • Funds reported $475K of Immix Biopharma stock for Q2 2022, up 35% quarter-over-quarter.
  • 4 funds opened new Immix Biopharma positions in Q2 2022 and 5 closed out, a net change of -1 holder.
  • The largest Immix Biopharma buyer in Q2 2022 was Geode Capital Management, an estimated $143K added.
  • The largest Immix Biopharma seller in Q2 2022 was Renaissance Technologies, an estimated $151K sold.

Based on aggregated 13F filings for Q2 2022.